kynamro: the malignancies are a “new concern”, page-58

What we're seeing here is a good lesson in market psychology.
It matters little whether the ISIS product has side effects, ALL drugs have side effects, its just a matter of how many and how negative the side effects are.
The growths that are a side effect arent peculiar to all Antisense drugs, they are peculiar to Kynamro, this specific drug.
It is not a reflection on other antisense models.
This is a classic case of the market showing its ignorance of an industry, and particularly about science.Have a look at Regulus, see how much that fell on Kynamro news.
If the Kynamro situation was relevant to all Antisense drugs one of the first shares to be hit would be Regulus.

Today has simply been a buying opportunity, if you believed in the antisense platform and the ANP future last week or last month, nothing has changed.
Anxiety and ignorance have effected ANPs price today, but another portion of the market without these 2 characteristics has just exploited these people to purchase more at a very good price.

ANP may get drugs to market, or they may never get drugs to market.But the Kynamro event has no effect on that outcome, at all.